Glemont film-coated tablets 10 mg blister No. 30




Glemont film-coated tablets are indicated for:
as an additional treatment of bronchial asthma in patients with persistent asthma of mild to moderate severity, insufficiently controlled by inhaled corticosteroids, as well as with insufficient clinical control of asthma with short-acting β-agonists used as needed. Symptomatic treatment of seasonal allergic rhinitis in patients with bronchial asthma. for the prevention of asthma, the dominant component of which is exercise-induced bronchospasm. for the relief of symptoms of seasonal and perennial allergic rhinitis.Composition
Active ingredient: montelukast;
1 film-coated tablet contains montelukast sodium equivalent to montelukast 10 mg;
Excipients: microcrystalline cellulose, lactose, croscarmellose sodium, hydroxypropylcellulose, magnesium stearate, Opadry yellow (hypromellose, hydroxypropylcellulose, titanium dioxide (E 171), yellow iron oxide (E 172), carnauba wax, red iron oxide (E172)).
Contraindication
Hypersensitivity to the components of the drug.
Method of application
The drug is intended for use in adults and children over 15 years of age.
Patients with asthma and allergic rhinitis (seasonal and perennial) 1 tablet 10 mg 1 time per day. For the treatment of asthma or asthma in combination with seasonal allergic rhinitis in adults and children over 15 years of age, the recommended dose is 1 tablet 10 mg 1 time per day, in the evening. To relieve the symptoms of allergic rhinitis, the time of administration is selected individually.
The dosage of the drug is the same for male and female patients.
Application features
Pregnant women
Montelukast can be taken during pregnancy only if, in the opinion of the doctor, the expected benefit to the mother outweighs the possible risk to the fetus.
Children
Used in children over 15 years of age. Children under 15 years of age should use the drug in the form of chewable tablets with the appropriate dosage.
Drivers
Montelukast is not expected to affect the patient's ability to drive or use machines. However, drowsiness or dizziness have been reported very rarely.
Overdose
There is no information on the treatment of overdose with montelukast. In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks, and in short-term studies, up to 900 mg/day for approximately one week, with no clinically significant adverse reactions.
Treatment is symptomatic.
Side effects
Infections and infestations: upper respiratory tract infections; Nervous system disorders: headache; Gastrointestinal disorders: abdominal pain; General disorders: thirst.Interaction
Montelukast can be administered with other drugs for the prevention or long-term treatment of asthma and the treatment of allergic rhinitis. In drug-drug interaction studies, the recommended dose of montelukast had no clinically significant effect on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (ethinylestradiol/norethindrone 35/1), terfenadine, digoxin, and warfarin.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Shelf life - 2 years.
There are no reviews for this product.
There are no reviews for this product, be the first to leave your review.
No questions about this product, be the first and ask your question.